Conducting a cost-effectiveness trial in oncology: justification and method

被引:0
作者
Lejeune, C. [1 ]
Binquet, C. [1 ]
Bonnetain, F. [1 ,2 ]
机构
[1] Univ Bourgogne, INSERM, U866, F-21079 Dijon, France
[2] Federat Francophone Cancerol Digest, F-21079 Dijon, France
关键词
cost-efficacy ratio; medico-economic trial; sample size; non-inferiority trial; superiority trial; cancer; SAMPLE-SIZE CALCULATION; CANCER;
D O I
10.1684/bdc.2009.0867
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The occurrence of scarce financial resources and the aim of an adequate allocation of available budgets for public community induce to conduct trials where primary endpoint could be a medico-economic criterion. In oncology, the emergent place of "stop and go" strategy and or the diminution of chemotherapy administration induce initially to demonstrate non-inferiority of these strategies for efficacy. Another underlying objective for these trials could be also to demonstrate the medico-economic superiority of these strategies. In this context, medico-economic trials using cost and efficacy composite endpoint as primary endpoint for therapeutical strategies comparison could be an interesting alternative of classical clinical trials using only an efficacy endpoint. Based on a review, the aim of this paper is to focus about design of medico-economic trials: objectives, methods and sample size calculations. triangle
引用
收藏
页码:603 / 607
页数:5
相关论文
共 9 条
  • [1] Al MJ, 1998, HEALTH ECON, V7, P327, DOI 10.1002/(SICI)1099-1050(199806)7:4<327::AID-HEC342>3.0.CO
  • [2] 2-U
  • [3] THE CE PLANE - A GRAPHIC REPRESENTATION OF COST-EFFECTIVENESS
    BLACK, WC
    [J]. MEDICAL DECISION MAKING, 1990, 10 (03) : 212 - 214
  • [4] Power and sample size calculations for stochastic cost-effectiveness analysis
    Briggs, AH
    Gray, AM
    [J]. MEDICAL DECISION MAKING, 1998, 18 (02) : S81 - S92
  • [5] DRUMMOND MF, 1997, METHODES EVALUATION
  • [6] Randomized clinical trial design for assessing noninferiority when superiority is expected
    Freidlin, Boris
    Korn, Edward L.
    George, Stephen L.
    Gray, Robert
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (31) : 5019 - 5023
  • [7] An opportunity cost approach to sample size calculation in cost-effectiveness analysis
    Gafni, A.
    Walter, S. D.
    Birch, S.
    Sendi, P.
    [J]. HEALTH ECONOMICS, 2008, 17 (01) : 99 - 107
  • [8] Moatti JP, 2003, B CANCER, V90, P1010
  • [9] OPTIMOX1:: A randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer -: A GERCOR study
    Tournigand, C
    Cervantes, A
    Figer, A
    Lledo, G
    Flesch, M
    Buyse, M
    Mineur, L
    Carola, E
    Etienne, PL
    Rivera, F
    Chirivella, I
    Perez-Staub, N
    Louvet, C
    André, T
    Tabah-Fisch, I
    de Gramont, A
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (03) : 394 - 400